secwatch / observer
8-K filed February 28, 2023, 6:59 PM ET ticker SUPN CIK 0001356576
earnings confidence high sentiment positive materiality 0.80

Supernus Q4/FY2022: total rev $667.2M (+15% YoY); Qelbree sales $61.3M; FY2023 rev guidance $580-620M

SUPERNUS PHARMACEUTICALS, INC.

2022-FY EPS reported $1.04 revenue$667,238,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. reported the full year ended December 31, 2022 results: revenue $667.2 million. Guidance initiated.

Period
the full year ended December 31, 2022
Revenue
$667.2 million
Guidance
initiated
Result
reported results
Exact text from the filing
Full Year 2022 total revenues of $667.2 million, a 15% increase compared to full year 2021
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. updated its the fourth quarter ended December 31, 2022 guidance (initiated).

Period
the fourth quarter ended December 31, 2022
Guidance
initiated
Result
reported results
Exact text from the filing
On February 28, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2022.
View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR
accession 0001356576-23-000008
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.